0000000000052147

AUTHOR

Sergio Castorina

showing 15 related works from this author

Diagnostic and prognostic value of three micrornas in environmental asbestiform fibers-associated malignant mesothelioma

2021

Fluoro-edenite (FE) is an asbestiform fiber identified in Biancavilla (Sicily, Italy). Environmental exposure to FE has been associated with a higher incidence of malignant mesothelioma (MM). The present study aimed to validate the predicted diagnostic significance of hsa-miR-323a-3p, hsa-miR-101-3p, and hsa-miR-20b-5p on a subset of MM patients exposed to FE and matched with healthy controls. For this purpose, MM tissues vs. nonmalignant pleura tissues were analyzed through droplet digital PCR (ddPCR) to evaluate differences in the expression levels of the selected miRNAs and their MM diagnostic potential. In addition, further computational analysis has been performed to establish the corr…

Oncologymedicine.medical_specialtyFluoro-edenitediagnosisMedicine (miscellaneous)AsbestoAsbestiformmedicine.disease_causeAsbestosArticleInternal medicinemicroRNAmedicineDigital polymerase chain reactionMesotheliomaMalignant mesotheliomaReceiver operating characteristicbusiness.industryIncidence (epidemiology)RMicroRNAEnvironmental exposuremedicine.diseaseasbestosPrognosisMedicinebusinessDiagnosi
researchProduct

Somatic loss of an EXT2 gene mutation during malignant progression in a patient with hereditary multiple osteochondromas

2015

Multiple osteochondromas (MO) is an autosomal-dominant skeletal disorder caused by mutations in the exostosin-1 ( EXT1 ) or exostosin-2 ( EXT2 ) genes. In this study, we report the analysis of the mutational status of the EXT2 gene in tumor samples derived from a patient affected by hereditary MO, documenting the somatic loss of the germline mutation in a giant chondrosarcoma and in a rapidly growing osteochondroma. The sequencing of all exons and exon–intron junctions of the EXT1 and EXT2 genes from blood DNA of the proband did not reveal any mutation in the EXT1 gene but did demonstrate the presence of the transition point mutation c.67C > T in the EXT2 gene, determining the introduction …

AdultMaleOsteochondromaCancer ResearchMultiple osteochondromaSettore MED/06 - Oncologia MedicaChondrosarcomaLoss of HeterozygositySettore BIO/11 - Biologia MolecolareBone NeoplasmsGene mutationBiologyN-Acetylglucosaminyltransferasesmedicine.disease_causeGermlineLoss of heterozygosityGermline mutationGeneticChondrosarcoma; Hereditary cancer; Hereditary multiple osteochondromas; Tumor suppressor gene; Molecular Biology; Genetics; Cancer ResearchSkeletal disorderGeneticsmedicineHumansTumor suppressor geneHereditary multiple osteochondromaMolecular BiologyGeneticsMutationChromosomes Human Pair 11DNA Neoplasmmedicine.diseaseHereditary cancerSettore MED/18 - Chirurgia GeneraleSettore MED/03 - Genetica MedicaMutationDisease ProgressionCancer Genetics
researchProduct

Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer

2005

<i>Background:</i> Induction chemotherapy followed by surgical resection or definitive radiotherapy for patients affected by stage IIIA N2 bulky non-small cell lung cancer (NSCLC) has been investigated in several trials. <i>Patients and Methods:</i> In this present study, 52 patients with stage IIIA N2 bulky NSCLC with cytologically or histologically confirmed mediastinal lymph node involvement received paclitaxel 175 mg/mq on day 1, carboplatin AUC 5 on day 1 and gemcitabine 1,000 mg/mq on day 1 and 8 every 3 weeks for three cycles as induction chemotherapy. <i>Results:</i> Objective response (4 complete remission and 36 partial remission) was achieved i…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.drug_classmedicine.medical_treatmentDeoxycytidineAntimetaboliteDisease-Free SurvivalDrug Administration ScheduleCarboplatinchemistry.chemical_compoundCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerAgedNeoplasm StagingChemotherapybusiness.industryRemission InductionInduction chemotherapyLung cancer Paclitaxel Carboplatin stage III ChemotherapyGeneral MedicineMiddle Agedmedicine.diseaseSurvival AnalysisGemcitabineGemcitabineCarboplatinrespiratory tract diseasesSurgeryRadiation therapyTreatment OutcomeOncologychemistryPaclitaxelChemotherapy AdjuvantFemaleRadiotherapy Adjuvantbusinessmedicine.drug
researchProduct

Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus

2016

Genetic changes involved in the metaplastic progression from squamous esophageal mucosa toward Barrett's metaplasia and adenocarcinoma are almost unknown. Several evidences suggest that some miRNAs are differentially expressed in Barrett's esophagus (BE) and esophageal adenocarcinoma. Among these, miR-143, miR-145, miR-194, miR-203, miR-205, miR-215 appear to have a key role in metaplasia and neoplastic progression. The aim of this study was to analyze deregulated miRNAs in serum and esophageal mucosal tissue biopsies to identify new biomarkers that could be associated with different stages of esophageal disease. Esophageal mucosal tissue biopsies and blood samples were collected and analyz…

MalePathologymedicine.medical_specialtyesophagitisEsophageal NeoplasmsSettore MED/06 - Oncologia MedicaSettore BIO/11 - Biologia MolecolareColumnar-lined oesophaguAdenocarcinomaSettore MED/08 - Anatomia PatologicaEsophageal Diseases03 medical and health sciencesBarrett's esophagus0302 clinical medicineMetaplasiamicroRNAmedicineHumansCirculating MicroRNAEsophagusMetaplasiamicroRNAbusiness.industryEsophageal diseaseEsophagitiBarrett's esophagus; Columnar-lined oesophagus; Esophagitis; Metaplasia; microRNA; OncologyBarrett's esophaguMiddle Agedmedicine.diseaseCirculating MicroRNAmedicine.anatomical_structureOncology030220 oncology & carcinogenesisBarrett's esophaguscolumnar-lined oesophagusDisease ProgressionAdenocarcinoma030211 gastroenterology & hepatologyFemalemedicine.symptombusinessEsophagitisResearch Paper
researchProduct

Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study

2005

Introduction: The primary tumour type most likely to metastasize to the brain is lung cancer. In heavily pre-treated patients, limited therapeutic option is available and the results of availability therapies reported in literature are disappointing. The present phase II study was designed to assess the efficacy and safety of temozolomide (TMZ) as palliative treatment for brain metastases (BrM) in NSCLC patients pre-treated with WBRT and at least one line of chemotherapy for metastatic brain disease. Material and methods: Temozolomide was administered orally at 150 mg/mq/day for five consecutive days for the first cycle, doses were increased to 200 mg/mq/day for 5 days every 28 days for sub…

Pulmonary and Respiratory MedicineOncologyMaleCancer Researchmedicine.medical_specialtyPalliative careLung NeoplasmsBrain metastasemedicine.medical_treatmentPhases of clinical researchAdministration OralPre-treatedInternal medicineCarcinoma Non-Small-Cell LungmedicineCarcinomaTemozolomideHumansAdverse effectLung cancerAntineoplastic Agents AlkylatingAgedChemotherapyTemozolomidebusiness.industryBrain NeoplasmsPalliative CareMiddle Agedmedicine.diseaseSurgeryDacarbazineTreatment OutcomeOncologyFemaleLung cancerbusinessProgressive diseasemedicine.drug
researchProduct

Reconstruction with a pectoralis major myocutaneous flap after left first rib and clavicular chest wall resection for a metastasis from laryngeal can…

2016

We presented a case of recurrent metastasis from epidermoid cancer that occurred in the left clavicle of a patient with a history of laryngeal cancer treated on April 2005 with extended hemilaryngectomy, neck dissection and chemoradiation therapy. On September 2008, he developed a left clavicular metastasis. The disease was initially well controlled by chemoradiotherapy but it recurred 17 months later. The optimal treatment plan was established by several multidisciplinary meetings and the patient subsequently underwent an en bloc resection of the left clavicle, first rib and all the other involved structures. Coverage of the thoracic defect was achieved using pectoralis major myocutaneous …

MalePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.medical_treatmentSettore MED/21 - Chirurgia ToracicaBone NeoplasmsRibsClavicular resection030204 cardiovascular system & hematologyMetastasisHemilaryngectomy03 medical and health sciences0302 clinical medicineChest wall involvementLaryngeal cancermedicineHumansThoracoplastyNeoplasm MetastasisThoracic WallLaryngeal NeoplasmsRib cagebusiness.industryBone metastasisCancerNeck dissectionGeneral MedicineMiddle AgedPlastic Surgery ProceduresMuscle flapmedicine.diseaseClavicleMyocutaneous FlapSurgerySettore MED/18 - Chirurgia GeneraleCardiothoracic surgeryChest wall involvement; Chest wall reconstruction; Clavicular resection; Laryngeal cancer; Muscle flap; Surgery; Pulmonary and Respiratory Medicine; Cardiology and Cardiovascular MedicineCarcinoma Squamous CellSurgeryNeoplasm Recurrence LocalbusinessChest wall reconstructionCardiology and Cardiovascular Medicine030217 neurology & neurosurgeryChemoradiotherapy
researchProduct

The role of intrinsic pathway in apoptosis activation and progression in Peyronie's Disease.

2014

Peyronie’s disease (PD) is characterized with formation of fibrous plaques which result in penile deformity, pain, and erectile dysfunction. The aim of this study was to investigate the activation of the intrinsic apoptotic pathway in plaques from PD patients. Tunica albuginea from either PD or control patients was assessed for the expression of bax, bcl-2 and caspases 9 and 3 using immunohistochemistry and by measurement of apoptotic cells using TUNEL assay. Bax overexpression was observed in metaplastic bone tissue, in fibroblasts, and in myofibroblast of plaques from PD patients. Little or no bcl-2 immunostaining was detected in samples from either patients or controls. Caspase 3 immunos…

AdultMalePathologymedicine.medical_specialtyArticle SubjectPenile Indurationlcsh:MedicineCaspase 3Apoptosisapoptosis peironie's disease urethraBone tissueGeneral Biochemistry Genetics and Molecular BiologySettore MED/24 - UrologiaYoung AdultBcl-2-associated X proteinPeyronie’s diseasemedicineIn Situ Nick-End LabelingHumansCaspaseAgedbcl-2-Associated X ProteinGeneral Immunology and MicrobiologybiologyStaining and LabelingOssificationCaspase 3Settore BIO/16 - Anatomia Umanalcsh:RGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryCaspase 9medicine.anatomical_structurePeyronie’s disease. ; Apoptosis; Immunohistochemistrybiology.proteinDisease Progressionmedicine.symptomPeyronie's diseaseMyofibroblastImmunostainingSignal TransductionResearch Article
researchProduct

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway

2016

// Daniela Massihnia 1,* , Antonio Galvano 1,* , Daniele Fanale 1 , Alessandro Perez 1 , Marta Castiglia 1 , Lorena Incorvaia 1 , Angela Listi 1 , Sergio Rizzo 1 , Giuseppe Cicero 1 , Viviana Bazan 1 , Sergio Castorina 2,3,** and Antonio Russo 1,** 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 Fondazione Mediterranea “G.B. Morgagni”, Catania, Italy 3 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy * These authors have contributed equally to this work ** Both the authors are last name Correspondence to: Antonio Russo, email: // Keywords : ER, HER2, PI3K/AKT/mTOR inhib…

Adult0301 basic medicineOncologymedicine.medical_specialtyPathologyAntineoplastic AgentsTriple Negative Breast NeoplasmsReviewTarget therapyPhosphatidylinositol 3-Kinases03 medical and health sciences0302 clinical medicineBreast cancerHER2Internal medicineDrug DiscoverymedicineCarcinomaHumansTriple negative breast cancerTarget therapyER; HER2; PI3K/AKT/mTOR inhibitor; Target therapy; Triple negative breast cancer; OncologySurvival rateProtein kinase BPI3K/AKT/mTOR pathwayTriple-negative breast cancerAgedClinical Trials as Topicbusiness.industryTOR Serine-Threonine KinasesAge FactorsMiddle Agedmedicine.diseaseOncogene Protein v-aktClinical trial030104 developmental biologyEROncology030220 oncology & carcinogenesisFemalePI3K/AKT/mTOR inhibitorbusinessSignal TransductionOncotarget
researchProduct

Nm-23-H1 expression does not predict clinical survival in colorectal cancer patients

2003

The gene Nm23, which encodes for a nucleoside diphosphate kinase, has been defined as a metastasis-suppressor gene because of the inverse correlation between its expression and the metastatic capacity of the tumor cells. For colorectal cancer, however, the findings are equivocal. The aim of our study was to assess, in 160 patients undergoing surgery for colorectal cancer (CRC), the expression of the Nm23-H1 protein and to evaluate its possible associations with traditional clinicopathologic variables, with DNA-ploidy and proliferative activity (S-phase fraction, SPF), and with disease-free and overall survival of patients. Nm23-H1 expressions were evaluated on paraffin-embedded tissue by im…

OncologyCytoplasmCancer Researchmedicine.medical_specialtyPathologyTime FactorsSettore MED/06 - Oncologia MedicaColorectal cancerBiologyDisease-Free SurvivalS PhaseInternal medicineNm23-H1 expressionmedicineHumansClinical significancePloidiesModels GeneticOncogeneCancerExonsGeneral MedicineNM23 Nucleoside Diphosphate KinasesCell cycleFlow CytometryPrognosismedicine.diseaseImmunohistochemistryColorectal cancerMolecular medicineOncologyTumor progressionNucleoside-Diphosphate KinaseProtein BiosynthesisDisease ProgressionImmunohistochemistryColorectal NeoplasmsCell Division
researchProduct

Resection of esophageal diverticulum through uniportal video-assisted thoracoscopic surgery

2018

Open surgery remains the standard strategy for management of esophageal diverticulum in symptomatic patients. However, in the last years an increasing number of minimally invasive approaches have been proposed for this issue in order to reduce the surgical trauma and favor a fast return to daily activity. Herein, we describe a novel technique as uniportal video-assisted thoracoscopic surgery (VATS) for performing resection of esophageal diverticulum. This procedure was successfully carried out in three consecutive patients with giant mid-esophageal diverticulum (mean size: 6.5±0.5 cm). The mean post-operative time was 121±10 minutes. The chest drain was removed 48 hours later in all cases a…

medicine.medical_specialtybusiness.industryOpen surgeryFistulauniportalGeneral Medicinemedicine.diseaseEsophageal diverticulumResectionSurgeryesophageal diverticulumMedicineSurgical TechniquebusinessProspective cohort studyVideo-thoracoscopicUniportal video assisted thoracoscopic surgeryHospital stayDiverticulum
researchProduct

A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung can…

2007

The optimal management of unresectable locally advanced non-small-cell lung cancer in older patients has not been defined to date. The present phase II study was planned to evaluate the activity and safety of platinum-based induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer. Patients received two cycles of paclitaxel (175 mg/m) and carboplatin (area under the curve: 5) day 1, every 3 weeks. Chemoradiotherapy (thoracic radiation therapy) was initiated on day 42 and consisted of 1.8 Gy daily, five times per week over 5 weeks (45.0 Gy target dose) followed by 10 2.0 Gy daily fractions. Concomitant chemotherapy wa…

MaleOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsSettore MED/06 - Oncologia MedicaLocally advancedPhases of clinical researchDisease-Free SurvivalDrug Administration ScheduleOlder patientsCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Lung cancerAgedNeoplasm StagingPharmacologybusiness.industryInduction chemotherapymedicine.diseaseCombined Modality TherapyNeoadjuvant TherapyOptimal managementConcurrent chemoradiotherapynon-small-cell lung cancerchemoradiotherapyOncologyFemaleNon small cellbusiness
researchProduct

A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC)

2006

Introduction: Lung cancer is the leading cause of tumour-related deaths in the elderly population but the optimal management of advanced NSCLC in older patients has not been defined to date. The present phase II study was planned to evaluate the efficacy and toxicity of the combination of carboplatin and paclitaxel in elderly patients with advanced NSCLC. Patients and methods: Patients (>70 years old) who had pathologically been proven to have a NSCLC and measurable lesions were treated with paclitaxel (175 mg/m2for 3 h) and carboplatin [area under the concentration-time curve (AUC = 5)] on day 1 every 3 weeks. Results: Forty patients were enrolled into the study. The median age was 74 year…

Pulmonary and Respiratory MedicineMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPopulationnon-small cell lung cancer (NSCLC)Phases of clinical researchNeutropeniaGastroenterologyCarboplatinchemistry.chemical_compoundElderlyNon-small cell lung cancerInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancereducationAgededucation.field_of_studyChemotherapyAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industrymedicine.diseaseSurvival AnalysisCarboplatinSurgeryLung NeoplasmTreatment OutcomeOncologychemistryItalyCarboplatin plus paclitaxelFemaleSurvival AnalysibusinessHuman
researchProduct

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

2016

// Daniele Fanale 1, * , Valeria Amodeo 1, * , Viviana Bazan 1, * , Lavinia Insalaco 1 , Lorena Incorvaia 1 , Nadia Barraco 1 , Marta Castiglia 1 , Sergio Rizzo 1 , Daniele Santini 2 , Antonio Giordano 3 , Sergio Castorina 4, 5, # , Antonio Russo 1, # 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 University Campus Bio-Medico, Department of Medical Oncology, Rome, Italy 3 Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA 4 Fondazione Mediterranea “G.B. Morgagni”, Catania, Italy 5 Department of Biomedic…

0301 basic medicineAntineoplastic AgentsBreast NeoplasmsBioinformatics03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancermicroRNAmedicineHumansZoledronic acidPI3K/AKT/mTOR pathwaybone metastasisBone Density Conservation AgentsDiphosphonatesMicroarray analysibusiness.industryGene Expression ProfilingImidazolesBone metastasisMicroRNA Expression Profilemedicine.diseaseActin cytoskeletonMolecular medicineBone metastasis; Breast cancer; Microarray analysis; miRNA expression profile; Zoledronic acid; Oncology030104 developmental biologyZoledronic acidOncologyBone metastasi030220 oncology & carcinogenesisMCF-7 CellsCancer researchmiRNA expression profilemicroarray analysisTranscriptomebusinessResearch Papermedicine.drug
researchProduct

Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin

2017

// Sergio Rizzo 1, * , Antonina Cangemi 1, * , Antonio Galvano 1, * , Daniele Fanale 1 , Silvio Buscemi 2 , Marcello Ciaccio 3 , Antonio Russo 1 , Sergio Castorina 4, 5, # and Viviana Bazan 1, # 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 Department of Internal and Specialistic Medicine (DIBIMIS), Laboratory of Clinical Nutrition, University of Palermo, Palermo, Italy 3 Section of Clinical Biochemistry and Clinical Molecular Medicine, Department of Biopathology and Medical Biotechnology, University of Palermo, U.O.C. Laboratory Medicine, Policlinico University Hospital, Palermo, Italy 4 Fondazione Mediterranea…

0301 basic medicineOncologymedicine.medical_specialtychemotherapy responseClinical nutritiondoxorubicin03 medical and health sciences0302 clinical medicineInternal medicinemicroRNAmedicineDoxorubicinTriple-negative breast cancershort term starvationtriple negative breast cancer cellsbusiness.industryCancerMicroRNAmedicine.diseaseMolecular medicinemicroRNAstriple negative breast cancer cell030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisImmunologyBreast cancer cellsbusinessChemotherapy response; Doxorubicin; MicroRNAs; Short term starvation; triple negative breast cancer cells; Oncologymedicine.drugResearch PaperOncotarget
researchProduct

Cycloastragenol as an Exogenous Enhancer of Chondrogenic Differentiation of Human Adipose-Derived Mesenchymal Stem Cells. A Morphological Study

2020

Stem cell therapy and tissue engineering represent a promising approach for cartilage regeneration. However, they present limits in terms of mechanical properties and premature de-differentiation of engineered cartilage. Cycloastragenol (CAG), a triterpenoid saponin compound and a hydrolysis product of the main ingredient in Astragalus membranaceous, has been explored for cartilage regeneration. The aim of this study was to investigate CAG&rsquo

MaleSettore BIO/17 - IstologiaSapogeninsTime Factorscycloastragenolhuman adipose-derived mesenchymal stem cellsArticleExtracellular matrixchemistry.chemical_compoundTissue engineeringchondrocyte phenotypemedicineHumansCycloastragenolAggrecanscartilage regenerationCell Shapelcsh:QH301-705.5AggrecanCells CulturedGlycoproteinsGlycosaminoglycansCell DeathChemistryCartilageRegeneration (biology)Mesenchymal stem cellCell DifferentiationMesenchymal Stem CellsSOX9 Transcription FactorGeneral MedicineMiddle AgedChondrogenesisCell biologycartilage regeneration; chondrocyte phenotype; cycloastragenol; human adipose-derived mesenchymal stem cells; hypertrophy; tissue engineeringmedicine.anatomical_structurelcsh:Biology (General)tissue engineeringFemaleCollagenhypertrophyChondrogenesiscartilage regeneration; chondrocyte phenotype; cycloastragenol; human adipose-derived mesenchymal stem cells; hypertrophy; tissue engineering; Aggrecans; Cell Death; Cell Differentiation; Cell Shape; Cells Cultured; Chondrogenesis; Collagen; Female; Glycoproteins; Glycosaminoglycans; Humans; Male; Mesenchymal Stem Cells; Middle Aged; SOX9 Transcription Factor; Sapogenins; Time FactorsCells
researchProduct